BofA Securities has upgraded Vir Biotechnology (NASDAQ:VIR) to buy from neutral saying that the market is underestimating the company's phase 3 combo treatment for severe liver disease caused ...
The GT classes will be featured at Virginia International Raceway in the final sprint race of the 2025 IMSA WeatherTech SportsCar Championship season. There are 23 cars entered across the GT Daytona ...
Evercore ISI initiated coverage of Vir Biotechnology (VIR) with an Outperform rating and $12 price target The firm sees a “compelling asymmetric setup” for the shares. Investors are underappreciating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback